Skip to main content
. 2009 Jul;94(7):998–1005. doi: 10.3324/haematol.2009.005819

Figure 1.

Figure 1.

(A) Forest plot of the included studies assessing HBV reactivation in lymphoma patients under treatment. The pooled effect of lamivudine prophylaxis justifies its preemptive use for the risk of HBV reactivation. (B) Forest plot of the included studies assessing HBV-associated mortality in lymphoma patients under treatment. Lamivudine prophylaxis is associated with an insignificant decline in mortality rates.